We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Metabolomic Profile Predicts Type II Diabetes Risk for Normal Weight Individuals

By LabMedica International staff writers
Posted on 05 May 2022
Print article
Image: Type II diabetes (Photo courtesy of 123rf.com)
Image: Type II diabetes (Photo courtesy of 123rf.com)

Employing a metabolomics approach, a team of Swedish investigator identified a panel of metabolites linked to obesity and found that normal weight individuals with this metabolic profile had increased risk for Type II diabetes and all-cause mortality compared with lean individuals with a healthy metabolome.

The "metabolome" includes four major classes of biological molecules: lipids, proteins/amino-acids, sugars, and nucleic acids.

Obesity is a key risk factor for Type II diabetes; however, up to 20% of diabetes patients are normal weight. Therefore, investigators aimed to identify metabolite patterns that were reproducibly predictive of BMI (body mass index) and subsequently to test whether lean individuals who expressed an obese metabolome were at hidden high risk of obesity-related diseases, such as Type II diabetes.

BMI is a measure of body fat based on height and weight, which is used to evaluate if a person is underweight, of normal weight, or obese. To determine whether they could identify a BMI-linked metabolome, investigators at Lund University (Sweden) measured levels of 108 metabolites associated with Type II diabetes in plasma samples from 7,663 individuals from two Swedish and one Italian population-based cohort. Ridge regression was used to predict BMI using the metabolites.

Individuals with a predicted BMI either higher (overestimated) or lower (underestimated) than their actual BMI were characterized as outliers and further investigated for obesity-related risk factors and future risk of Type II diabetes and mortality.

The participants were divided into five groups based on the relationship between the BMI linked to weight and height and their metabolic BMI. The five groups were (1) individuals with a normal BMI based on weight, height, and metabolism; (2) overweight individuals based on weight, height, and metabolism; (3) obese individuals based on weight, height, and metabolism. (4) Individuals in this group had a normal BMI based on height and weight. Their metabolic BMI had metabolic alterations associated with obesity. (5) Individuals in this group had a metabolic BMI which was lower than their BMI based on weight and height.

Results revealed that the metabolome could predict BMI in all cohorts. The overestimated group had a BMI similar to individuals correctly predicted as normal weight, had a similar waist circumference, were not more likely to change weight over time, but had a two times higher risk of future Type II diabetes and an 80% increased risk of all-cause mortality. These associations remained after adjustments for obesity-related risk factors and lifestyle parameters.

Senior author Dr. Olle Melander, professor of internal medicine at Lund University, said, “We hope that our research will be used to identify individuals with a hidden risk of developing the disease. If we can find these individuals before the disease debuts, we would be able to initiate preventive actions. This could potentially save society a lot of money as Type II diabetes often leads to a variety of different complications.”

The study was published in the March 14, 2022, online edition of the journal Diabetes Care.

Related Links:
Lund University

Gold Supplier
Proficiency Assessment Software
CellaVision Proficiency Software
New
3-Part Diff Hematology Analyzer
DLB3
New
Silver Supplier
3-Part Hematology Analyzer
DH26
New
Auto Clinical Chemistry Analyzer
Mispa Clinia Plus

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.